Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026)

Quarterly Gains from Investment Securities rose 42.59% to -$8939.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$149679.7 through Mar 2026, up 15.56% year-over-year, with the annual reading at -$173511.3 for FY2024, 52.39% down from the prior year.

Oculis Holding AG's Gains from Investment Securities history spans 4 years, with the latest figure at -$8939.0 for Q1 2026.

  • Gains from Investment Securities came in at -$8939.0 for Q1 2026, down from $7247.3 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $65386.6 in Q4 2023 to a low of -$213537.7 in Q2 2023.
  • The 4-year median for Gains from Investment Securities is -$11456.8 (2024), against an average of -$27429.1.
  • Year-over-year, Gains from Investment Securities plummeted 302.51% in 2024 and then surged 143.69% in 2025.
  • Oculis Holding AG's Gains from Investment Securities stood at $65386.6 in 2023, then tumbled by 302.51% to -$132416.5 in 2024, then skyrocketed by 105.47% to $7247.3 in 2025, then tumbled by 223.34% to -$8939.0 in 2026.
  • Per Business Quant, the three most recent readings for OCS's Gains from Investment Securities are -$8939.0 (Q1 2026), $7247.3 (Q2 2025), and -$15571.5 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Oculis Holding AG 24.51 Bn 24.21 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -8,939.03
Mar 31, 2026 -8,939.03
Jun 30, 2025 7,247.34
Jun 30, 2025 7,247.34
Mar 31, 2025 -15,571.51
Mar 31, 2025 -15,571.51
Dec 31, 2024 -132,416.53
Dec 31, 2024 -132,416.53
Sep 30, 2024 -12,696.28
Sep 30, 2024 -12,696.28
Jun 30, 2024 -16,586.90
Jun 30, 2024 -16,586.90
Mar 31, 2024 -11,456.82
Mar 31, 2024 -11,456.82
Dec 31, 2023 65,386.56
Dec 31, 2023 65,386.56
Sep 30, 2023 26,039.51
Sep 30, 2023 26,039.51
Jun 30, 2023 -213,537.71
Jun 30, 2023 -213,537.71
Mar 31, 2023 10,811.63
Mar 31, 2023 10,811.63